Jeffery Darby, SVP – Sales and Marketing of Dorman Products, Inc. (DORM) Just Sold Shares; Diplomat Pharmacy, Inc. (DPLO) Covered By 6 Bulls

Among 15 analysts covering Diplomat Pharmacy (NYSE:DPLO), 6 have Buy rating, 0 Sell and 9 Hold. Therefore 40% are positive. Diplomat Pharmacy had 45 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, March 2 by Deutsche Bank. Bank of America upgraded the stock to “Neutral” rating in Wednesday, October 14 report. The firm has “Mkt Perform” rating given on Thursday, November 3 by Avondale. Robert W. Baird downgraded Diplomat Pharmacy, Inc. (NYSE:DPLO) on Thursday, November 16 to “Neutral” rating. On Monday, December 11 the stock rating was upgraded by Leerink Swann to “Outperform”. Robert W. Baird maintained it with “Buy” rating and $24.0 target in Friday, October 27 report. The firm has “Market Perform” rating by Leerink Swann given on Tuesday, November 7. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) has “Buy” rating given on Tuesday, September 12 by Needham. The rating was upgraded by Credit Suisse to “Hold” on Thursday, January 25. Wells Fargo maintained the shares of DPLO in report on Tuesday, February 27 with “Market Perform” rating. See Diplomat Pharmacy, Inc. (NYSE:DPLO) latest ratings:

08/03/2018 Broker: Barclays Capital Rating: Overweight New Target: $27 Initiates Coverage On
02/03/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
27/02/2018 Broker: Robert W. Baird Rating: Hold New Target: $22.0 Maintain
27/02/2018 Broker: Needham Rating: Buy New Target: $28.0 Maintain
27/02/2018 Broker: Wells Fargo Rating: Market Perform Old Target: $21.5 New Target: $25 Maintain
27/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $32 New Target: $30 Maintain
09/02/2018 Broker: Lake Street Rating: Buy New Target: $35 Initiates Coverage On
02/02/2018 Broker: Deutsche Bank Rating: Hold New Target: $29.0 Downgrade
25/01/2018 Broker: Credit Suisse Rating: Hold New Target: $28.0 Upgrade
24/01/2018 Broker: Mizuho Rating: Hold New Target: $25.0 Maintain

As exposed in an electronic form filed with the Washington-based SEC on March 09, 2018, Jeffery Darby, SVP – Sales and Marketing of Dorman Products Inc and an insider with a special knowledge about the firm, made a sale of 1,100 shares of the firm for the amount of $80,043 USD calculated with average price per share of $72.8. Currently, Mr. Jeffery, has 14,106 shares, which accounts for 0.04% of Dorman Products Inc’s market cap.

Investors sentiment increased to 1.89 in 2017 Q3. Its up 0.45, from 1.44 in 2017Q2. It increased, as 22 investors sold Diplomat Pharmacy, Inc. shares while 37 reduced holdings. 21 funds opened positions while 64 raised stakes. 49.42 million shares or 3.34% more from 47.82 million shares in 2017Q2 were reported. Broadview Advsrs Ltd Company accumulated 441,975 shares or 1.33% of the stock. Gru One Trading Limited Partnership has 2,050 shares for 0% of their portfolio. 32,018 are held by Royal Bancshares Of Canada. Pub Sector Pension Inv Board stated it has 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). 29,250 are owned by Thrivent Fincl For Lutherans. 41,749 were reported by State Of Tennessee Treasury Department. Northern Tru Corp has invested 0.01% in Diplomat Pharmacy, Inc. (NYSE:DPLO). D E Shaw &, New York-based fund reported 327,585 shares. Citadel Advisors Limited Company accumulated 18,413 shares. New York State Teachers Retirement has 38,102 shares. Aperio Limited Liability Corp has 20,007 shares for 0% of their portfolio. Wells Fargo And Mn has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Oppenheimer Asset Mgmt reported 29,079 shares. Carroll Fin has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). 757,300 are owned by Financial Bank Of America Corp De.

The stock increased 4.96% or $1.06 during the last trading session, reaching $22.41. About 1.18 million shares traded or 34.51% up from the average. Diplomat Pharmacy, Inc. (NYSE:DPLO) has declined 40.48% since March 11, 2017 and is downtrending. It has underperformed by 57.18% the S&P500.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $1.64 billion. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It has a 98.29 P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Among 9 analysts covering Dorman Products (NASDAQ:DORM), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dorman Products has $8500 highest and $44 lowest target. $61.33’s average target is -15.45% below currents $72.54 stock price. Dorman Products had 19 analyst reports since October 14, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, July 6 by Jefferies. On Wednesday, October 14 the stock rating was initiated by Barrington Research with “Outperform”. The rating was maintained by Jefferies on Monday, September 11 with “Hold”. The firm earned “Hold” rating on Wednesday, July 27 by Jefferies. FBR Capital maintained it with “Outperform” rating and $62 target in Thursday, October 29 report. The firm has “Strong Buy” rating by CL King given on Wednesday, January 3. The rating was maintained by Jefferies on Wednesday, October 18 with “Hold”. Sidoti initiated the stock with “Buy” rating in Wednesday, December 23 report. The firm has “Buy” rating given on Wednesday, January 3 by C.L. King. On Wednesday, August 9 the stock rating was maintained by Jefferies with “Hold”.

Dorman Products, Inc. supplies automotive replacement parts, automotive hardware, brake products, and household hardware to the automotive aftermarket and mass merchandise markets in the United States, Canada, Mexico, Europe, the Middle East, and Australia. The company has market cap of $2.42 billion. It offers original equipment dealer products, such as intake manifolds, exhaust manifolds, window regulators, radiator fan assemblies, tire pressure monitor sensors, exhaust gas recirculation coolers, and complex electronics modules; fluid reservoirs, variable valve timing components, and integrated door lock actuators; and fasteners, including oil drain plugs, wheel bolts, and wheel lug nuts. It has a 23.18 P/E ratio. The firm also provides automotive replacement parts comprising door handles, keyless remotes and cases, emission control products, and oil dipsticks, as well as door hinge repairs; and application specific and general automotive hardware consisting of body hardware, general automotive fasteners, oil drain plugs, and wheel hardware.

The stock increased 0.04% or $0.03 during the last trading session, reaching $72.54. About 120,853 shares traded. Dorman Products, Inc. (NASDAQ:DORM) has risen 57.51% since March 11, 2017 and is uptrending. It has outperformed by 40.81% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: